Explore Business Standard
Eli Lilly
Authorities in Gurugram have uncovered a racket involved in the manufacturing and sale of fake Mounjaro (tirzepatide) injections - used for treating diabetes and obesity - with the arrest of two people and issued a nationwide alert to trace counterfeit batches. Following the confiscation of counterfeit injections, pharmaceutical company Eli Lilly, the manufacturer of Mounjaro, reacted to the seizure. "We have been made aware of a recent development in relation to the seizure of suspicious and counterfeit products that allegedly carry our product brand name Mounjaro (Tirzepatide)...Lilly takes patient safety extremely seriously and welcomes regulatory authority's action against illicit medicines," Eli Lilly and Company (India) spokesperson said. Drug Control Officer Amandeep Chauhan on Monday said investigators are probing the network behind the illegal operation and tracking all those linked to the racket. A Health Department team raided a residential society in Sector 62, Gurugram
Union Commerce and Industry Minister Piyush Goyal held a meeting with Patrik Jonsson, Executive Vice President and President of Lilly International, discussing India's growth trajectory and the company's expanding presence in the country.Sharing details of the meeting on X, Goyal said on Friday that the discussions focused on Eli Lilly and Company's increasing operations and investments in India, and ways to further strengthen the 'Make in India for the world' initiative."Held a meeting with Patrik Jonsson, Executive VP and President, Lilly International, USA. We discussed the India growth story, Eli Lilly & Company's expanding operations and investments in India, and the steps to further strengthen Make in India for the world," the post read.Earlier in the day, Piyush Goyal held a virtual meeting with Harry Theoharis, Greece's Deputy Minister of Foreign Affairs. He highlighted that the discussions revolved around deepening cooperation between India and Greece."Held a virtual ...
Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.